Subgroup Analyses of Disclosure of Any Past 12-Month Substance Use Among Primary Care and Adolescent Medicine Patient Groups by Screening Tool
Abbreviations: BSTAD, Brief Screener for Tobacco, Alcohol, and Drugs; NA, not applicable; S2BI, Screening to Brief Intervention; TAPS, Tobacco, Alcohol, Prescription Medication, and Other Substances.Unless indicated otherwise, values are presented as No. (%) of participants.Among the 242 participants randomized to S2BI screening, 2 did not receive it. The S2BI assesses past 12-month use of tobacco, alcohol, cannabis, prescription medication, e-cigarette, illegal drugs, inhalants, and herbs or synthetic drugs.Among the 253 participants randomized to BSTAD screening, 1 did not receive it. The BSTAD assesses past 12-month use of nicotine/tobacco, alcohol, cannabis, prescription medications, and illegal drugs.Among the 262 participants randomized to TAPS screening, 2 did not complete it. The TAPS screening assesses past 12-month use of tobacco, alcohol, illegal drugs (including cannabis), and prescription medications.A question on cannabis use in the past 12 months was included in the aggregated “illegal drugs” question in the TAPS. No tests were performed for these items due to lack of comparability. Column percentages are shown. χIn a subgroup analysis, we assessed the prevalence of disclosure of any past 12-month substance use, using the total subgroup of 752 participants from adolescent medicine and primary care who completed 1 of the 3 screening tools (S2BI, BSTAD, and TAPS). Since the rates of self-disclosure of past 12-month substance use were near universal among patients in the SUD treatment program, they were excluded from this exploratory analysis (